KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Equity Ratio (2018 - 2025)

Historic Equity Ratio for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to 0.83.

  • Castle Biosciences' Equity Ratio fell 318.03% to 0.83 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.83, marking a year-over-year decrease of 318.03%. This contributed to the annual value of 0.86 for FY2024, which is 58.1% down from last year.
  • Latest data reveals that Castle Biosciences reported Equity Ratio of 0.83 as of Q3 2025, which was down 318.03% from 0.84 recorded in Q2 2025.
  • Castle Biosciences' Equity Ratio's 5-year high stood at 0.96 during Q1 2021, with a 5-year trough of 0.83 in Q3 2025.
  • In the last 5 years, Castle Biosciences' Equity Ratio had a median value of 0.89 in 2021 and averaged 0.89.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 3089.65% in 2021, then plummeted by 659.18% in 2022.
  • Quarter analysis of 5 years shows Castle Biosciences' Equity Ratio stood at 0.89 in 2021, then increased by 0.25% to 0.89 in 2022, then decreased by 3.27% to 0.86 in 2023, then fell by 0.58% to 0.86 in 2024, then dropped by 3.28% to 0.83 in 2025.
  • Its last three reported values are 0.83 in Q3 2025, 0.84 for Q2 2025, and 0.88 during Q1 2025.